Suppr超能文献

变应原免疫疗法候选者的特征。

Characteristics of candidates for allergen immunotherapy.

作者信息

Ciprandi Giorgio, Incorvaia Cristoforo, Dell'Albani Ilaria, Masieri Simonetta, Cavaliere Carmine, Puccinelli Paola, Frati Franco

机构信息

IRCCS-A.O.U. San Martino, Genoa, Italy.

出版信息

Allergy Rhinol (Providence). 2013 Summer;4(2):e77-81. doi: 10.2500/ar.2013.4.0061.

Abstract

Allergic rhinitis (AR) may be cured by allergen immunotherapy (AIT). However, patient characteristics for prescribing AIT are not well defined. This study aimed at evaluating the patient's profile to be a candidate for AIT in a cohort of patients suffering from AR, evaluated in 20 Italian Allergy or Ear, Nose, and Throat Centers. The study has been performed on 198 patients (98 men; mean age, 26.8 years) with AR (assessed by Allergic Rhinitis and Its Impact on Asthma [ARIA] criteria). The kind and the number of prescribed allergen extracts, type of diagnosis, severity of symptoms, and patient's perception of symptoms and drug use were evaluated. Patients were subdivided in AIT-treated and without AIT (as controls) subgroups. Most of the patients (69.7%) had persistent AR with moderate-severe symptoms. The mean number of sensitization was 3.4. ARIA classification and sensitization number did not affect AIT choice, but the type of allergen was relevant. AIT-treated patients had milder symptoms than controls if assessed by doctors, but AIT patients perceived more severe symptoms and larger drug use than controls. This study shows that the choice of AIT is based on patient's perception and type of allergen, but number of sensitizations, symptom severity assessed by doctors, and ARIA classification are not relevant factors. The key message might be that it is always relevant to pay attention to the complaints referred by the patient.

摘要

变应性鼻炎(AR)可通过变应原免疫疗法(AIT)治愈。然而,关于开具AIT处方的患者特征尚无明确界定。本研究旨在评估在20家意大利过敏或耳鼻喉中心接受评估的AR患者队列中,适合接受AIT的患者概况。该研究纳入了198例AR患者(98例男性;平均年龄26.8岁)(根据变应性鼻炎及其对哮喘的影响[ARIA]标准进行评估)。评估了所开具变应原提取物的种类和数量、诊断类型、症状严重程度以及患者对症状和药物使用的认知。患者被分为接受AIT治疗组和未接受AIT组(作为对照组)。大多数患者(69.7%)患有伴有中重度症状的持续性AR。平均致敏原数量为3.4种。ARIA分类和致敏原数量不影响AIT的选择,但变应原类型具有相关性。如果由医生评估,接受AIT治疗的患者症状比对照组轻,但接受AIT治疗的患者比对照组感觉到更严重的症状且使用了更多药物。本研究表明,AIT的选择基于患者的认知和变应原类型,但致敏原数量、医生评估的症状严重程度以及ARIA分类并非相关因素。关键信息可能是始终关注患者所述的主诉是很重要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/94d0/3793117/52f7ed4e0383/arh0021300610001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验